Arix Bioscience Share Discussion Threads

[supernumerary] 28/4/2021 14:05

12 o'clock today:

I'm surprised that 'The terms of the transaction will result in a small increase in Arix's holding value of Amplyx.' If that's true Pfizer aren't paying enough!

[pinemartin9] 28/4/2021 13:42

Missed that, which one?

[n0rbie] 28/4/2021 13:12

Another winner - portfolio company sold to Pfizer

[ohisay] 19/4/2021 14:15

There is it seems a seller and the buyback is mopping up his exit at a price they both like ..?!
As someone suggested earlier it might be an ex director.

[eaaxs06] 15/4/2021 16:43

It certainly doesn't seem to be working wonders so far, Lennonsalive.

83k @ 189.5p today?

Good luck everyone, Sid.

[lennonsalive] 14/4/2021 17:45

Share buy backs a waste of time, never work.

[eaaxs06] 14/4/2021 17:23

The more and more times IC mention Arix as a buy, the less and less notice anyone takes of their recommendation. I guess anyone who was that interested in it bought on the first tip then ignored acting on any further write ups.

Obviously the word is out that the company are buyers at 190p, hence the price being stuck at 188/192 all week long. They always seem to be able to buy the stock at mid price, which is a good trick if you can manage it, I wish I could.

Good luck everyoine, Sid.

[ayl30] 14/4/2021 08:49

ExtractArtios management played key roles in AstraZeneca's discovery of Lynparza, a treatment for advanced ovarian cancer, another reason why both Merck and Novartis are backing them. Moreover, the collaborations strongly suggest that Arix has backed another major winner for its shareholders, having previously realised US$185m (£139m) for its 6.8 per cent stake in Velos Bio, a company that was acquired by Merck for US$2.75bn at the end of 2020.Arix invested £13.8m for a 12.4 per cent fully diluted stake in Artios and the holding has a modest carrying value of £19m. However, investment bank Jefferies valued the Artios stake at £49m after the Merck announcement, but before news of the Novartis collaboration. Jefferies' NAV estimate of £339m (250p a share) includes cash of £185m (136p a share), so effectively Arix's investment portfolio of listed and unquoted companies is in the price for half book value. That's a harsh valuation given that Artios is only one of several portfolio companies that are approaching key milestones over the next 12 months.I suggested buying Arix shares, at 168p, in my market-beating 2021 Bargain Shares Portfolio, and the news from Artios adds further weight to the investment case. Buy.

[pinemartin9] 14/4/2021 08:48

What does he say? Can you post please?

[pinemartin9] 14/4/2021 08:47

Target 500M NAV by 2023...that's about twice current NAV.

[ayl30] 14/4/2021 07:41

S Thompson in IC features this online today as a continued 'buy'

[t0pgrader] 12/4/2021 23:10

Do your own research first

[ugandalad] 11/4/2021 15:49

IC's Thomson seems to be ignoring the interplay with Acacia which has stopped two new directors being appointed. They have worries about the current Board not having a strong enough investment team and wasting the cash reserve. I only recently bought in myself and with the Board willing to talk to the 12% shareholder I think the intervention maybe a good thing even if they are advised by Neil Woodford.

[pinemartin9] 11/4/2021 10:58

It's essentially an extremely focused fund. You pays your chances...high risk, high reward. Just take a look into the individual holdings. The management so far seem very shrewd in what they've purchased. I'm happy holding here to see what value comes out. This meets a nice objective in my SIPP and gives me exposure to some very early stage Biotech plays that I'd struggle to otherwise. My only concern is how they have used the recent windfall. I'd have liked to have seen a special dividend or stakes in additional business. However, the state buyback should increase EPS in the longterm. I'm just cynical of the motives and hope the BoD don't reward themselves signifier options. That said if it incentives them so be it.

[ayl30] 11/4/2021 09:28

See post 263 below!

[researchcentre123] 11/4/2021 09:19

I've just come across this on a screener as it seems cheap - is there some kind of business here other than the cash it's sitting on? I'm guessing they sold out a holding which generated the low or (ie a one-off sale) but am wondering if there is any real upside potential here or good/bad story? I'd appreciate any views one way or the other. Thank you

[chesil356] 09/4/2021 15:26

It's not going to move properly until the current large seller has finished, last time I looked they were shifting 1% a month and he was just under 3%. Basically the large seller who is an ex Director (check back over the news feed) I think will be Finished by June. He is selling more per day than Arix is buying, You can't trust the buy and sell data it isn't correct, it's easy to check just do a dummy buy and sell and you get the real prices. This is massively undervalued at the moment and that is the reason.

[ohisay] 09/4/2021 14:53

Artios Pharma, a company backed by venture capital company Arix Bioscience (ARIX:190p), has entered into a three-year research collaboration with drug giant Novartis to discover and validate next-generation DNA Damage Response (DDR) targets to enhance Novartis' Radioligand Therapies (RLT). Artios is a leading DDR company that is developing a pipeline of precision medicines for the treatment of cancer.

...Artios management played key roles in AstraZeneca’s discovery of Lynparza, a treatment for advanced ovarian cancer, another reason why both Merck and Novartis are backing them. Moreover, the collaborations strongly suggest that Arix has backed another major winner for its shareholders, having previously realised US$185m (£139m) for its 6.8 per cent stake in Velos Bio, a company that was acquired by Merck for US$2.75bn at the end of 2020.

Arix invested £13.8m for a 12.4 per cent fully diluted stake in Artios and the holding has a modest carrying value of £19m. However, investment bank Jefferies valued the Artios stake at £49m after the Merck announcement, but before news of the Novartis collaboration. Jefferies' NAV estimate of £339m (250p a share) includes cash of £185m (136p a share), so effectively Arix’s investment portfolio of listed and unquoted companies is in the price for half book value. That’s a harsh valuation given that Artios is only one of several portfolio companies that are approaching key milestones over the next 12 months.

[pinemartin9] 08/4/2021 18:30

Can't see it being downwards. Portfolio businesses doing well. Money will flow in Biotech and Pharma. share price supported by buy backs. Maybe time for another chunck methinks?

[ohisay] 08/4/2021 17:45

The chart suggests a breakout one way or another ..

[eaaxs06] 07/4/2021 18:49

So, even one of the 5 'sells' was actually a buyback by Arix making 65 buys to 4 sells in todays trades.

That's 594k shares bought, 24k sold. and the price has stubbornly stuck with 187/8 to 191/2 (bid to offer) all day long!

Don't stand too close, if that spring breaks it could take someones eye out.

Good luck everyone, Sid.

[pinemartin9] 07/4/2021 15:26

Coiled spring...hopefully the impact of the continued buy backs will start to build. Just need some positive news or a rabbit out of the hat with a portfolio business and this could surge 20%

[eaaxs06] 07/4/2021 15:13

55 buy orders, and only 5 sells today, yet the price still doesn't move!

Good luck everyone, Sid.

[ohisay] 07/4/2021 14:09

I'm still buying .Artios looks like it might be a remarkable investment ..